Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

46 results about "CXCL10" patented technology

C-X-C motif chemokine 10 (CXCL10) also known as Interferon gamma-induced protein 10 (IP-10) or small-inducible cytokine B10 is an 8.7 kDa protein that in humans is encoded by the CXCL10 gene. C-X-C motif chemokine 10 is a small cytokine belonging to the CXC chemokine family.

Methods of diagnosing and treating multiple sclerosis by detecting a biomarker in the cerebrospinal fluid

Provided herein are methods and immune biomarkers that identify progression and treatment options for multiple sclerosis (MS). Also provided are materials and methods for the prognosis, staging, and monitoring of MS in a sample and include methods of determining a subject as being at risk of developing MS. The methods include detecting at least one biomarker, such as CXCL13, CXCL10, CD27, NEFL, CCL4, and / or CCL3 in cerebrospinal fluid (CSF) in the subject; and administering a pharmaceutically effective amount of a treatment (e.g., tolebrutinib and potentially one or more additional therapies, such as an anti-CD20 therapy) to the subject.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES +1

Application of cynarin as cGAS-STING signaling pathway inhibitor in preparation of anti-inflammatory drugs

The invention belongs to the technical field of biological medicine, and particularly relates to application of cynarin as a cGAS-STING signal channel inhibitor in preparation of anti-inflammatory drugs. It is found for the first time that cynarin can inhibit phosphorylation of STING and translocation of STING by influencing the stability of STING spatial conformation, so that channel downstream protein activation is inhibited, nuclear translocation of IRF3 is hindered, expression of a series of interferon-induced related genes such as IFN-beta, CXCL10 and ISG15 is inhibited, finally secretion of IFN-beta can be hindered, cGAS-STING inflammatory response can be inhibited by targeting STING, and the application of cynarin in inhibiting cGAS-STING inflammatory response is achieved. A new thought and a new means are provided for developing an auxiliary treatment method aiming at STING related inflammations.
Owner:GUANGZHOU MEDICAL UNIV

Biomarker combination for diagnosing liver cancer, Logistic model and application thereof

The invention provides a biomarker combination for early diagnosis of liver cancer. The biomarker combination is composed of an RNA biomarker and a protein biomarker, the RNA type biomarkers comprise LINC01554, miR-222, SNORD31, circMIRIAF, SNHG8 and RNU5E-1, and the RNA type biomarkers are used for detecting the RNA type biomarkers. The protein type biomarkers comprise SIGLEC5, CXCL10, AFP (Alpha Fetoprotein) and PIVKA-II (Phosphatidylserine Virus Kinase Activator-II) The invention also provides an application of the biomarker combination in preparation of a liver cancer early diagnosis kit, and a Logistic model constructed based on the biomarker combination. The kit and the Logistic model provided by the invention can be suitable for diagnosis of early stage, middle stage and late stage of liver cancer. The Logistic model and the diagnosis standard of the Logistic model have high sensitivity and specificity on the diagnosis of the liver cancer.
Owner:ZHEJIANG UNIV

Application of isodan leaf emodin in preparation of CXCL10 inhibitor

The invention belongs to the technical field of medicine, particularly relates to application of isodan-leaf emodin in preparation of a CXCL10 inhibitor, and particularly relates to application of the isodan-leaf emodin in treatment of sepsis lung injury, and by establishing a sepsis lung injury model induced by cecum ligation puncture (CLP), the application of the isodan-leaf emodin in preparation of the CXCL10 inhibitor is established. It is proved that the polyphenol monomer drug isodan leaf emodin can significantly improve lung tissue pathological damage, reduce the level of inflammatory factors in lung tissue, inhibit oxidative stress reaction and improve the survival rate of a CLP model. Experiments show that the isodan leaf emodin with the dosage of 25 mg / kg can relieve pulmonary edema and inflammatory response by inhibiting secretion of CXCL10, and a new scheme is provided for treatment of sepsis-related lung injury.
Owner:HENAN ACADEMY OF MEDICAL SCIENCES

Prediction model for judging prognosis and immunotherapy response of ovarian cancer based on machine learning and application

The invention relates to a prediction model for judging prognosis and immunotherapy response of ovarian cancer based on machine learning. The prediction model comprises the following steps: determining gene expression quantities of eight markers, namely ANGPTL4, AREG, CXCL10, FANCB, GMPR, IGF1, LYG1 and WNK 1. The invention also provides a gene combination kit for predicting the prognosis and immunotherapy response of the ovarian cancer and application of the gene combination kit. The invention provides a prediction model aiming at ovarian cancer, which is used for judging the prognosis of a patient, can assist in guiding immunotherapy and prognosis judgment, and helps to realize personalized treatment aiming at a specific patient. Experiments and tumor big data support the prognosis model, the prognosis and immunotherapy response of a patient can be effectively predicted by integrating various biological and clinical data, powerful support can be provided for individualized treatment, a treatment scheme can be optimized, and the survival rate and life quality of the patient can be improved.
Owner:JINSHAN HOSPITAL AFFILIATED TO FUDAN UNIV (EYE DISEASE PREVENTION & TREATMENT CENT OF JINSHAN DISTRICT RES CENT FOR CHEM INJURY EMERGENCY & CRITICAL MEDICINE OF SHANGHAI MUNICIPAL HEALTH COMMISSION)

High-throughput assays for cell migration, chemotaxis, and function

The assay system allows for the study of cell migration through tissue-associated extracellular matrix under chemokine gradients within a modular assay platform. Using this assay system, activated CD3+ T cells migrating towards chemokines (CXCL10 and CXCL12) and chemokine mimetics (CXCR3 agonists) were detected, quantified, and studied. This assay system facilitates drug discovery and the study of the microenvironment, stimuli, and responding cells.
Owner:GLAXOSMITHKLINE INTPROP DEV LTD

High-throughput assay for cell migration, chemotaxis, and function

An assay system permits study of cell migration through tissue-relevant extracellular matrices under a chemokine gradient within a modular assay platform. Activated CD3+ T-cells were detected, quantified, and studied as they migrated towards chemokines (CXCL10 and CXCL12) and chemokine mimetics (CXCR3 agonist) using the assay system. Discovery of drugs, and the study of microenvironments, stimuli, and responding cells are facilitated by the assay system.
Owner:GLAXOSMITHKLINE INTPROP DEV LTD

Specific targeting peptide CIBB composition capable of protecting ovarian injury caused by tumor and application of specific targeting peptide CIBB composition

PendingCN119074946Aprotection from tumor damageBinding does not affectCosmetic preparationsPeptide/protein ingredientsInflammatory factorsReceptor
The invention discloses a specific targeting peptide CIBB composition capable of protecting ovarian injury caused by tumors and application of the specific targeting peptide CIBB composition. The composition comprises CIBB-1 as shown in SEQ ID NO. 1 and CIBB-2 as shown in SEQ ID NO. 2. Due to the fact that CIBB specifically prevents combination of CXCL10 and an ovarian receptor IL18R1, CIBB does not affect combination of other factors such as IL18 and IL18R1, and normal physiological functions of other inflammatory factors in an ovary are not interfered. The CIBB does not target a tumor-related receptor, so that the CIBB does not influence other therapy for inhibiting tumors; as a polypeptide drug, compared with an inhibitor, CIBB has the remarkable advantages of high specificity, high efficiency, high safety, low immunogenicity, high membrane permeability, low cost and the like; the CIBB can be combined with various tumor treatment schemes, so that the ovarian function and the reproductive power of women suffering from tumors in the childbearing period are ensured.
Owner:THE FIRST AFFILIATED HOSPITAL OF ANHUI MEDICAL UNIV

Application of AMG-487 in preparation of medicine for treating retinopathy of premature infant

The invention belongs to the technical field of pharmacy, and particularly relates to application of AMG-487 in preparation of a medicine for treating premature infant retinopathy, and the medicine is used for treating the premature infant retinopathy by blocking combination of CXCL10 or / and CXCR3 in the ROP high oxygen period. Through research, the inventor finds that expression of CXCL10 in a blood sample of a patient with ROP is remarkably increased, TFR, HIF-1alpha, STAT3 and PTGS2 in a ferroptosis pathway have remarkable correlation with the CXCL10, AMG-487 can inhibit combination of CXCL10 / CXCR3 so as to reduce expression of TFR, HIF-1alpha, STAT3 and PTGS2 in the ferroptosis pathway, the effect of preventing and / or treating the retinopathy (ROP) of premature infants is achieved, ROP can be effectively treated, and the application prospect is wide. The compound is expected to become a novel medicine for treating ROP diseases and has important clinical application value.
Owner:TIANJIN EYE HOSPITAL

Application of Nup85 targeting inhibitor in preparation of medicine for preventing or treating hepatocellular carcinoma

The invention discloses application of a targeted Nup85 inhibitor in preparation of a medicine for preventing or treating hepatocellular carcinoma, and relates to the technical field of biological medicine and tumor immunotherapy. The invention provides an application of a targeted Nup85 inhibitor in preparation of a medicine for preventing or treating hepatocellular carcinoma. The inhibitor prevents and / or treats hepatocellular carcinoma by enhancing CD8 + T cell functions, enhancement of the CD8 + T cell functions is realized by regulating STAT1 / CCL5 / CXCL10 pathways, and Nup85 reduces expression of CCL5 and CXCL10 by inhibiting nuclear translocation of phosphorylated STAT1, so that infiltration and activation of CD8 + T cells are inhibited. The invention discloses an immune escape mechanism that Nup85 inhibits CD8 + T cell infiltration by inhibiting p-STAT1 nuclear translocation and down-regulating CCL5 / CXCL10 expression in liver cancer for the first time, provides a new liver cancer immunotherapy target, and broadens the application of nucleopore protein in tumor immunotherapy; the target Nup85 inhibitor can be obtained through a conventional means, a new clinical application direction of the target Nup85 inhibitor is defined, and the target Nup85 inhibitor has good clinical transformation and development prospects.
Owner:SUN YAT SEN UNIVERSITY CANCER CENTER (CANCER HOSPITAL AFFILIATED TO SUN YAT SEN UNIVERSITY CANCER RESEARCH INSTITUTE OF SUN YAT SEN UNIVERSITY)

Immunostimulatory bacteria for converting macrophages to a phenotype suitable for treatment and companion diagnostics for identifying subjects for treatment

Provided are methods for treating cancer by converting tumor-resident macrophages to a hybrid M1 / M2 macrophage phenotype, which has attributes that are advantageous for cancer therapy. Hybrid markers (lower than M2 and higher than M1) include SPP1, CD209, and CD206, and inducible markers include MERTK, C1QC, IFNa, IFNb, CXCL10, 4-1BBL, and MYC. The method includes administering a therapeutic agent that achieves the phenotype conversion. The therapeutic agent, such as a delivery vehicle that includes an immunostimulatory bacterium with genomic modifications, is designed to inhibit type I IFN by not inducing or resulting in sufficient TLR2, TLR4, TLR5 responses. The therapeutic agent also encodes a payload that encodes an immunostimulatory protein, e.g., a cytokine, and a modified intracytoplasmic DNA / RNA sensor that constitutively induces type I IFN, such as a modified STING protein. The combination of the properties of the payload immunostimulatory protein and the therapeutic delivery vehicle, when administered, results in macrophages with a hybrid phenotype. The therapeutic agent is administered to a subject identified as having a tumor that contains proliferating M2 macrophages.
Owner:ACTYM THERAPEUTICS INC

Oncolytic virus and cancer treatment using same

PendingAU2025211304A1CXCL10Cancer treatment
The present invention provides: an oncolytic virus such as a conditionally replicating adenovirus carrying the CXCL10 gene; the oncolytic virus additionally carrying the IL-2 gene and / or the GM-CSF gene on the same viral genome; a combination of the oncolytic virus and a separate oncolytic virus carrying the IL-2 gene and / or the GM-CSF gene; and a cancer treatment agent comprising any of the aforementioned oncolytic viruses or a combination thereof as an active ingredient.
Owner:KAGOSHIMA UNIV +1

Application of curcumin in preparation of medicine for treating retinopathy of premature infants

The invention belongs to the technical field of pharmacy, and particularly relates to application of curcumin in preparation of a medicine for treating premature infant retinopathy, and the medicine is used for treating premature infant retinopathy by reducing the expression level of CXCL10 or / and CXCR3 in the OIR hyperxia period. Through research, the inventor finds that the expression of CXCL10 in a blood sample of a patient with ROP is remarkably increased, TFR, HIF-1alpha, STAT3 and PTGS2 in a ferroptosis pathway have remarkable correlation with the CXCL10, curcumin can inhibit the expression of TFR, HIF-1alpha, STAT3 and PTGS2 in the ferroptosis pathway so as to reduce the expression of CXCL10, the effect of preventing and / or treating the retinopathy (ROP) of premature infants is achieved, ROP can be effectively treated, and the curative effect is good. The compound is expected to become a novel medicine for treating ROP diseases and has important clinical application value.
Owner:TIANJIN EYE HOSPITAL

High-throughput assay for cell migration, chemotaxis, and function

An assay system permits study of cell migration through tissue-relevant extracellular matrices under a chemokine gradient within a modular assay platform. Activated CD3+ T-cells were detected, quantified, and studied as they migrated towards chemokines (CXCL10 and CXCL12) and chemokine mimetics (CXCR3 agonist) using the assay system. Discovery of drugs, and the study of microenvironments, stimuli, and responding cells are facilitated by the assay system.
Owner:GLAXOSMITHKLINE INTPROP DEV LTD

Cxcl10 binding proteins and uses thereof

The present invention relates to C-X-C motif chemokine ligand 10 (CXCL10) binding proteins and their use in methods of detecting and / or diagnosing a condition in a subject, including determining the level of CXCL10 in a subject. Specific antibodies that bind total CXCL10 (full length, N-terminally truncated and citrullinated) and antibodies that bind active CXCL10 (full length) are used to measure the level of total CXCL10 and active CXCL10 in ovarian cancer patient samples. The calculated ratio between active CXCL10 and total CXCL10 is lower in patients with malignant disease compared to patients with benign tumors or healthy individuals, and this calculated ratio is the basis for methods of diagnosing malignant disease, monitoring tumor burden and disease progression.
Owner:HUDSON INST OF MEDICAL RES

Application of MAT2A inhibitor in preparation of medicine for preventing and / or treating inflammation

The invention provides an application of a MAT2A inhibitor in preparation of a medicine for preventing and / or treating inflammation. A cell experiment result shows that the MAT2A inhibitor has a remarkable inhibition effect on an inflammatory cell model after administration, and mRNA expression levels of various inflammatory factors TNF-alpha, IFN-gamma, IL-1beta, IL-6, IL-12a and CXCL10 in cells are remarkably reduced; the invention provides a new direction for treating inflammatory diseases.
Owner:XIANGYA HOSPITAL CENT SOUTH UNIV

Application of cytokine CXCL10 in depression and / or anxiety disorder

The invention relates to an application of a cytokine CXCL10 in depression and / or anxiety disorder. Specifically, the inventor verifies that the cytokine CXCL10 can effectively treat depression and / or anxiety disorders.
Owner:SHANGHAI JIAOTONG UNIV

Pharmaceutical composition for promoting anti-tumor immunity and application of pharmaceutical composition in preparation of drugs for treating tumors

The invention relates to the technical field of biological medicine, and discloses a medicine composition for promoting anti-tumor immunity and application of the medicine composition in preparation of medicine for treating tumors, the medicine composition comprises small molecules and a PD-1 antibody, and the small molecules have the following structure: # imgabs0 #. The micromolecule obtained by the invention can target REXO4 enzyme and inhibit the enzyme activity of the REXO4 digestion R-loop structure, so that the increase of the R-loop structure of tumor cells is promoted, and the purposes of promoting infiltration of anti-tumor immune cells and inhibiting tumor growth are achieved. The small molecule can promote generation of I-type interferon related chemotactic factors Cxcl10 of tumor cells, so that recruitment of anti-tumor related immune cells is caused, an immune checkpoint inhibitor therapy is enhanced, and the aim of killing the tumor cells is achieved.
Owner:TIANJIN MEDICAL UNIV +1

Use of SHP1 in the manufacture of a medicament for the treatment of chronic pain

PendingCN122424305ATyrosineSpinal cord
The application belongs to the technical field of biological medicine, and particularly relates to the use of SH2 domain-containing protein tyrosine phosphatase 1 (SHP1) in the preparation of a drug for treating chronic pain, in particular to the use of SHP1 in the preparation of a drug for treating chronic pain by regulating the morphology of spinal cord astrocytes, the integrity of the blood-spinal cord barrier and the STAT1-CXCL10-CXCR3 neuroimmune signal axis, and a chronic pain treatment strategy based on the signal axis. The application first discloses that SHP1 in spinal cord astrocytes directly dephosphorylates STAT1, inhibits the transcription of CXCL10 and the subsequent infiltration of T lymphocytes into the spinal cord, and discloses the core analgesic mechanism, thereby establishing SHP1 as a new target for treating chronic pain, and opening up a new way for the precise treatment of clinical chronic pain, especially neuropathic pain.
Owner:FUDAN UNIVERSITY

Targeting B7-H3 chimeric antigen receptor-T cell expressing CXCL10 and application of targeting B7-H3 chimeric antigen receptor-T cell in tumor treatment

The invention relates to a targeted B7-H3 chimeric antigen receptor-T cell for expressing CXCL10 and application of the targeted B7-H3 chimeric antigen receptor-T cell in tumor treatment. The targeted B7-H3 chimeric antigen receptor-T cell comprises a targeted B7-H3 chimeric antigen receptor, a chemotactic factor CXCL10 and application of the targeted B7-H3 chimeric antigen receptor-T cell in tumor treatment. The chemotactic factor provided by the invention can effectively promote the effect of CAR-T cell immunotherapy.
Owner:SHAOXING RES INST OF ZHEJIANG UNIV

Metabolic dysfunction-associated steatohepatitis biomarker compositions and applications thereof

A MASH biomarker composition and an application thereof is provided, the biomarker composition including a protein marker and / or clinical biochemical marker for the diagnosis of MASLD and / or MASH, the protein marker being selected from CXCL10, CK-18, P62 / SQSTM1, CA3, SQLE, Pro-C3 or one or more of FGF21; the clinical biochemical marker is selected from one or more of BMI, HDL-C, HbA1c, ALT, AST, LDL-C, TG, TC, ALP, or PLT. Biomarker compositions were established by logistic regression and artificial intelligence methods as diagnostic markers for the diagnosis of MASLD and MASH with high sensitivity, specificity, positive predictive value, and negative predictive value in the diagnosis of MASH, independent of age, gender, or metabolic status.
Owner:SHENZHEN RES INST THE CHINESE UNIV OF HONG KONG

Methods for diagnosing and treating multiple sclerosis

Provided herein are methods and immune biomarkers for identifying multiple sclerosis (MS) progression and treatment options. Materials and methods for prognosing, staging, and monitoring MS in a sample are also provided, including methods for determining a subject as at risk for developing MS. The methods include detecting at least one biomarker, such as CXCL13, CXCL10, CD27, NEFL, CCL4, and / or CCL3, in the cerebrospinal fluid (CSF) of a subject, and administering a pharmaceutically effective amount of a therapy (e.g., trebrutinib and potentially one or more additional therapies, e.g., an anti-CD20 therapy) to the subject.
Owner:PRINCIPIA BIOPHARMA INC +1

Gene expression markers and treatment of multiple sclerosis

To provide markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.SOLUTION: A method of identifying a mammalian subject with multiple sclerosis (MS) or at risk of developing MS, comprising: measuring an expression level of at least one gene selected from the group consisting of TIMP1, LRG1, CXCL1, CXCL5, CXCL10, IL-8, NFκBIZ, YKL40, and G-CSF in a biological sample taken from the subject, wherein an increased level of expression compared to a control indicates that the subject has MS or is at risk of developing MS.SELECTED DRAWING: None
Owner:GENENTECH INC

Methods of diagnosing and treating multiple sclerosis by detecting biomarkers in cerebrospinal fluid

Provided herein are methods and immune biomarkers for identifying progression and therapeutic selection of multiple sclerosis (MS). Also provided are materials and methods for prognosis, staging, and monitoring of MS in a sample, and including methods of determining that a subject is at risk of developing MS. The method comprises detecting at least one biomarker, such as CXCL13, CXCL10, CD27, NEFL, CCL4, and / or CCL3, in the cerebrospinal fluid (CSF) of the subject; and administering to the subject a pharmaceutically effective amount of a treatment (e.g., tobutinib and potentially one or more additional therapies, such as an anti-CD20 therapy).
Owner:PRINCIPIA BIOPHARMA INC +1

Application of miR-491-5p in sepsis complicated with acute lung injury

The invention discloses application of miR-491-5p in sepsis complicated with acute lung injury. The research finds that the miR-491-5p is highly expressed in peripheral blood of a sepsis patient and peripheral blood of a cecum ligation perforation model mouse; the reagent for inhibiting the expression of the miR-491-5p in the hPAEC cell inhibits the expression of pro-inflammatory genes IL-1beta, TNF-alpha, IL-6, CXCL10 and CRP of the hPAEC cell, inhibits the secretion of inflammatory factors IL-1beta, TNF-alpha and IL-6 of the hPAEC cell, promotes the proliferation activity of the hPAEC cell, promotes the migration activity of the hPAEC cell, inhibits the apoptosis of the hPAEC cell, and inhibits the expression of the miR-491-5p in the hPAEC cell. The inhibition of miR-491-5p expression provides a new possible treatment means for the treatment of sepsis complicated with acute lung injury.
Owner:ZHONG SHAN PEOPLES HOSPITAL

Use of a CXCL 10 inhibitor for the treatment of transplant vasculopathy

Transplantation is a surgical operation to replace a failed organ or tissue with a healthy organ or tissue, from a donor to a recipient. It is a common remedy in case of failure of an organ or tissue as failure to replace the failed organ or tissue usually condemns the patient or forces him to undergo extensive treatment. Every recipient is at risk of transplant rejection. While significant progress has been made to control the immune reaction of the recipient against the donor transplant, little is known about how to prevent chronic rejection. The Inventors herein demonstrate that administration of a CXCL10 inhibitor in vivo in a mouse model of transplant vasculopathy decreases transplant vasculopathy after aortic allograft. Accordingly, the present invention relates to a method of treating a subject at risk or suffering from transplant vasculopathy comprising administering to said subject a therapeutically effective amount of a CXCL10 inhibitor.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3

Engineered immune cell expressing chemokine 10 and interleukin 15

Provided are an engineered immune cell expressing CXCL10 and IL15 and the use thereof. The immune cell can further express a chimeric antigen receptor or a T cell receptor. The engineered immune cell can enhance the recruitment and accumulation of immune cells, enhance the killing efficiency of immune cells on target cells, and enhance the treatment effect of immune cells on tumors, such as solid tumors.
Owner:BEIJING DCTY BIOTECH CO LTD

System for identifying whether people are in active tuberculosis infection state or not from gene expression of peripheral blood and application of system

The invention provides a system for identifying whether a person is in an active tuberculosis infection state or not from gene expression of peripheral blood and application of the system, and the system is used for simultaneously detecting expression levels of human FCGR1A gene, FCGR1B gene, GBP5 gene, GBP6 gene, CXCL10 gene and KLF2 gene so as to determine whether the person is in the active tuberculosis infection state or not. The sensitivity of combined detection of the six genes is 91.18%, the specificity reaches 86.84%, the target requirement for terminating tuberculosis in 2035 published by the United National Health Organization is met, and TB high-risk groups can be screened out by the method and then diagnosed by a diagnosis method.
Owner:BRIGHT-INNOVATION BIOMED CO LTD +1

Application of PD-1 inhibitor in preparation of medicine for treating prostatic cancer with TP53 gene mutation

The invention provides application of a PD-1 inhibitor to preparation of a medicine for treating prostatic cancer with TP53 gene mutation, and relates to the technical field of medicine. The medicine comprises a therapeutically effective amount of the PD-1 inhibitor and a pharmaceutically acceptable carrier auxiliary component thereof. The PD-1 inhibitor and Mutp53 are related to epithelial lineage, metabolic reprogramming and recombination of CAF and immune cell population, so that the improvement of tumor immunity accessibility is promoted together. In a comprehensive view, the discovery reveals a direct mechanism relation among TP53 high-frequency mutation, Cxcl10 signal transduction and ICB treatment sensitivity, and a new biological insight and a potential strategy are provided for layering and combined treatment of patients suffering from CRPC.
Owner:THE FIRST AFFILIATED HOSPITAL OF ANHUI MEDICAL UNIV